Market Overview

JP Morgan Upgrades Orexigen Therapeutics to Overweight

Related OREX
Orexigen Therapeutics Gains On Diet Pill Nod From European Committee
Friday's Big Gainers With High Short Interest

Orexigen Therapeutics (NASDAQ: OREX) was upgraded from Neutral to Overweight with a $10 price target by J.P. Morgan on Thursday following FDA approval of the drug Belviq (lorcaserin).

Arena Pharmaceuticals (NASDAQ: ARNA) scored a big hit this week after this decision to approve the obesity drug Belviq. Following this news Arena shares rose 30 percent, but this has caused banks like J.P. Morgan to monitor other pharmaceutical companies trying to treat obesity.

J.P. Morgan analyst Cory Kasimov wrote that he believes Orexigen will in fact be the biggest winner from the obesity interest, despite the fact that its own Contrave drug is still a couple of years away from FDA approval.

"We have been and continue to be confident in Contrave's (partnered with Takeda) ultimate approvability based on the drug's positive Phase 3 program and FDA AdCom (13-7 vote in favor of approval in Dec 2010)," Kasimov said. "We'd further remind investors that the company has a second unencumbered obesity asset in Empatic that has completed Phase 2b testing and could advance to Phase 3 if VVUS's Qnexa is approved. The bottom line is that we expect this valuation discrepancy to narrow over time, and as such, we would be buyers of OREX at current levels."

The obesity field was shaken on Wednesday when Arena's Belviq drug received FDA approval. According to Medical News Today, Belviq "is the first prescription diet drug to receive US federal approval in over a decade. It works by activating the serotonin 2C receptor in the brain, an effect that may help the patient feel full after eating smaller amounts of food and thereby eat less."

"The approval of this drug, used responsibly in combination with a healthy diet and lifestyle, provides a treatment option for Americans who are obese or are overweight and have at least one weight-related comorbid condition," Dr. Janet Woodcock, director of the Center for Drug Evaluation and Research at the FDA told the press.

On Thursday afternoon, Orexigen Therapeutics traded at about $5.80, up roughly 19 percent. Arena Pharmaceuticals traded at about $10.20, down roughly 10.3 percent.

Follow me @BCallwood.

Latest Ratings for OREX

DateFirmActionFromTo
Oct 2013Cowen & CompanyInitiates Coverage onOutperform
Jan 2013Piper JaffrayInitiates Coverage onOverweight
Oct 2012Jefferies & CompanyMaintainsHold

View More Analyst Ratings for OREX
View the Latest Analyst Ratings

Posted-In: Belviq Center for Drug Evalutaion and Research ContraveAnalyst Color News Upgrades FDA Analyst Ratings Best of Benzinga

 

Related Articles (ARNA + OREX)

Around the Web, We're Loving...

Get Benzinga's Newsletters